My Application Form Status

Check the status of your application form with Angel Broking.
  • Companies
  • Everything else
Search

Dishman Pharmaceuticals and Chemicals Ltd Research Report - 21st Jan 2016

Pharmaceutical | Published on Nov 20th 2015

IT

For 2QFY2016, Dishman Pharmaceuticals and Chemicals (Dishman) posted lower than expected results on the sales front while a higher other income aided the net profit to come in marginally higher than expected. The company posted a 4.8% yoy dip in sales to Rs374cr V/s Rs392cr in 2QFY2015. Sales for 2QFY2016 declined 4.8% yoy to Rs374cr V/s an expected Rs429cr and V/s Rs392cr in 2QFY2015. The CRAMS segment (Rs269.6cr) posted a decline of 4.1% while the other segment (Rs103.9cr) posted a dip of 6.4% yoy. On the operating front, the GPM came in at 75.8% V/s 72.3% expected and V/s 69.7% in 2QFY2015. However, in spite of the same, the OPM came in at 22.5% V/s 22.0% expected and V/s 20.5% in 2QFY2015. The net profit consequently came in at Rs36.5cr V/s Rs35.6cr expected and V/s Rs33.4cr in 2QFY2015, a yoy growth of 9.4%. The other income during the period came in at Rs15.1cr V/s Rs7.8cr in 2QFY2015. We maintain our Neutral stance on the stock. Results lower than expected on the sales front: Sales for 2QFY2016 declined 4.8% yoy to Rs374cr V/s an expected Rs429cr and V/s Rs392cr in 2QFY2015. The CRAMS segment (Rs269.6cr) posted a decline of 4.1% while the other segment (Rs103.9cr) posted a dip of 6.4% yoy. On the operating front, the GPM came in at 75.8% V/s 72.3% expected and V/s 69.7% in 2QFY2015. However, in spite of the same, the OPM came in at 22.5% V/s 22.0% expected and V/s 20.5% in 2QFY2015. The net profit consequently came in at Rs36.5cr V/s Rs35.6cr expected and V/s Rs33.4cr in 2QFY2015, a yoy growth of 9.4%. The other income during the period came in at Rs15.1cr V/s Rs7.8cr in 2QFY2015. Outlook and valuation: We expect Dishman’s net sales and net profit to grow at a CAGR of 10.0% and 15.9%, respectively, over FY2015-17E. At current levels, Dishman is trading at 16.5x its FY2017E earnings. We believe the current valuations are fair, discounting the recovery well; hence, we maintain our Neutral rating on the stock.

Download Full Report

Accumulate

CMP 329
Target Price
Investment Period12 Months

Stock Info

MCAP BSE (Rs in Cr)3,812.94
MCAP NSE (Rs in Cr)3,815.36
P/E (x)19.35
EPS (Rs.)12.21
BV (Rs.)67.03
Div Yield (%)0.42
FV (Rs.)2.00
P/BV (x)2.30
EV/Sales (x)2.99
EV/EBITDA (x)13.36

Shareholding Pattern (%)

Promoter61.0
Foreign16.0
Public & Others14.0
Institution7.0
Corporate2.0
Grand Total100.0

Trade Securely

AngelEye

Portfolio Tracking & Trading Application View Demo